Laura DeForge

8.4k total citations · 1 hit paper
54 papers, 5.8k citations indexed

About

Laura DeForge is a scholar working on Immunology, Molecular Biology and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, Laura DeForge has authored 54 papers receiving a total of 5.8k indexed citations (citations by other indexed papers that have themselves been cited), including 28 papers in Immunology, 23 papers in Molecular Biology and 22 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in Laura DeForge's work include Monoclonal and Polyclonal Antibodies Research (19 papers), Immune Response and Inflammation (11 papers) and Cell Adhesion Molecules Research (7 papers). Laura DeForge is often cited by papers focused on Monoclonal and Polyclonal Antibodies Research (19 papers), Immune Response and Inflammation (11 papers) and Cell Adhesion Molecules Research (7 papers). Laura DeForge collaborates with scholars based in United States, France and Switzerland. Laura DeForge's co-authors include Daniel G. Remick, Jeanine L. Bussiere, J. Kenney, Avi Ashkenazi, David A. Lawrence, Hartmut Koeppen, Scot A. Marsters, Zahra Shahrokh, Iphigenia L. Koumenis and Andrea Hebert and has published in prestigious journals such as Nature, Journal of Biological Chemistry and Journal of Clinical Investigation.

In The Last Decade

Laura DeForge

53 papers receiving 5.6k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Safety and antitumor activity of recombinant soluble Apo2 ligand

1999 1.9k citations Laura DeForge et al. Journal of Clinical Investigation profile →

Peers

Countries citing papers authored by Laura DeForge

Since Specialization

Citations

This map shows the geographic impact of Laura DeForge's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Laura DeForge with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Laura DeForge more than expected).

Fields of papers citing papers by Laura DeForge

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Laura DeForge. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Laura DeForge. The network helps show where Laura DeForge may publish in the future.

Co-authorship network of co-authors of Laura DeForge

This figure shows the co-authorship network connecting the top 25 collaborators of Laura DeForge. A scholar is included among the top collaborators of Laura DeForge based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Laura DeForge. Laura DeForge is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	A novel immunoassay to measure total serum lymphotoxin‐α levels in the presence of an anti-LTα therapeutic antibody 2015 ·Journal of Immunological Methods ·Judy Young, Allen Nguyen, Zhihua Qiu, Yong Ying, Xiaoying Gao, Chae Reed, Anan Chuntharapai, Rong Deng, Jeff Lutman, Jane L. Grogan, Wai Lee Wong, Laura DeForge	1
2	Complement Inhibition in Cynomolgus Monkeys by Anti–Factor D Antigen-Binding Fragment for the Treatment of an Advanced Form of Dry Age-Related Macular Degeneration 2014 ·Journal of Pharmacology and Experimental Therapeutics ·Kelly M. Loyet, (unknown), (unknown), (unknown), Xiangdan Wang, Jihong Yang, Kha Le, (unknown), Philip E. Hass, Menno van Lookeren Campagne, Peter C. Haughney, Alyssa Morimoto, Lisa A. Damico‐Beyer, Laura DeForge	40
3	Effects of altered FcγR binding on antibody pharmacokinetics in cynomolgus monkeys 2013 ·mAbs ·Maya K. Leabman, Y. Gloria Meng, Robert F. Kelley, Laura DeForge, Kyra J. Cowan, Suhasini Iyer	83
4	Subcutaneous bioavailability of therapeutic antibodies as a function  of FcRn binding affinity in mice 2012 ·mAbs ·Rong Deng, Y. Gloria Meng, Kwame Hoyte, Jeff Lutman, Yanmei Lu, Suhasini Iyer, Laura DeForge, Frank‐Peter Theil, Paul J. Fielder, Saileta Prabhu	66
5	Anti-Factor D Fab Specifically Inhibits the Alternative Complement Pathway: In vitro Characterization and in vivo Effects Following Administration to Cynomolgus Monkeys 2010 ·Investigative Ophthalmology & Visual Science ·Kelly M. Loyet, (unknown), (unknown), (unknown), Manda Wong, Alyssa Morimoto, Menno van Lookeren Campagne, Laura DeForge, Peter C. Haughney, Lisa A. Damico	1
6	Targeting the Alternative Pathway of Complement in AMD With a Factor D Selective Antibody 2010 ·Investigative Ophthalmology & Visual Science ·Menno van Lookeren Campagne, Kenneth J. Katschke, Ping Wu, Christian Wiesmann, Robert F. Kelley, Kelly M. Loyet, Laura DeForge, Philip E. Hass, Peter C. Haughney, Lisa A. Damico	2
7	Evaluation of heterophilic antibody blocking agents in reducing false positive interference in immunoassays for IL-17AA, IL-17FF, and IL-17AF 2010 ·Journal of Immunological Methods ·Laura DeForge, Kelly M. Loyet, Donnie Delarosa, (unknown), (unknown), Anan Chuntharapai, James Lee, Phil Hass, Nathan Wei, Michael J. Townsend, Jianyong Wang, Wai Lee Wong	26
8	Lymphotoxin-αβ heterotrimers are cleaved by metalloproteinases and contribute to synovitis in rheumatoid arthritis 2010 ·Cytokine ·Judy Young, Xin Yu, Kristen Wolslegel, Allen Nguyen, (unknown), Eugene Y. Chiang, Ganesh Kolumam, Nathan Wei, Wai Lee Wong, Laura DeForge	38
9	Technology comparisons for anti-therapeutic antibody and neutralizing antibody assays in the context of an anti-TNF pharmacokinetic study 2009 ·Journal of Immunological Methods ·Kelly M. Loyet, Rong Deng, Wei‐Ching Liang, (unknown), Henry B. Lowman, Laura DeForge	17
10	Species-dependent serum interference in a sandwich ELISA for Apo2L/TRAIL 2007 ·Journal of Immunological Methods ·Laura DeForge, Danny Shih, Derek Kennedy, Klára Tótpál, Anan Chuntharapai, Gregory L. Bennett, (unknown), Patricia Siguenza, Wai Lee Wong	8
11	Synthetic anti-BR3 antibodies that mimic BAFF binding and target both human and murine B cells 2006 ·Blood ·Chingwei V. Lee, S.G. Hymowitz, Heidi J.A. Wallweber, Nathaniel C. Gordon, Karen L. Billeci, Siao‐Ping Tsai, Deanne M. Compaan, (unknown), Qian Gong, Robert F. Kelley, Laura DeForge, Flavius Martin, Melissa A. Starovasnik, Germaine Fuh	48
12	Structure of C3b in complex with CRIg gives insights into regulation of complement activation 2006 ·Nature ·Christian Wiesmann, Kenneth J. Katschke, Jianping Yin, Karim Y. Helmy, Micah Steffek, Wayne J. Fairbrother, Scott A. McCallum, (unknown), Laura DeForge, Philip E. Hass, Menno van Lookeren Campagne	187
13	Substrate Capacity Considerations in Developing Kinase Assays 2004 ·Assay and Drug Development Technologies ·Laura DeForge, Andrea G. Cochran, Sherry Yeh, Brian Robinson, Karen L. Billeci, Wai Lee Wong	6
14	IL-8 single-chain homodimers and heterodimers: Interactions with the chemokine receptors CXCR1, CXCR2, and DARC 1997 ·Protein Science ·Steven R. Leong, C A Hébert, Henry B. Lowman, Jun Liu, (unknown), Laura DeForge, Beth L. Gillece-Castro, (unknown)	43
15	Exchanging Interleukin-8 and Melanoma Growth-stimulating Activity Receptor Binding Specificities 1996 ·Journal of Biological Chemistry ·Henry B. Lowman, (unknown), Laura DeForge, (unknown), Beth L. Gillece-Castro, James H. Bourell, Wayne J. Fairbrother	70
16	Interleukin-1 receptor blockade improves survival and hemodynamic performance in Escherichia coli septic shock, but fails to alter host responses to sublethal endotoxemia. 1992 ·Journal of Clinical Investigation ·E Fischer, Michael A. Marano, Kimberly J. Van Zee, Craig S. Rock, A S Hawes, William A. Thompson, Laura DeForge, J S Kenney, Daniel G. Remick, Duane C. Bloedow	250
17	Sandwich Elisa for Detection of Picogram Quantities of Interleukin-8 1991 ·Immunological Investigations ·Laura DeForge, Daniel G. Remick	65
18	Kinetics of TNF, IL-6, and IL-8 gene expression in LPS-stimulated human whole blood 1991 ·Biochemical and Biophysical Research Communications ·Laura DeForge, Daniel G. Remick	188
19	IL-8 in septic shock, endotoxemia, and after IL-1 administration 1991 ·The Journal of Immunology ·Kimberly J. Van Zee, Laura DeForge, E Fischer, Michael A. Marano, J S Kenney, Daniel G. Remick, S F Lowry, Lyle L. Moldawer	250
20	Noninvasive Assessment of Lipid Disposition in Treated and Untreated Atherosclerotic Rabbits 1989 ·Pharmaceutical Research ·Laura DeForge, Susan W. Schwendner, (unknown), Daniel McConnell, Raymond E. Counsell	4

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact